Pieris Pharmaceuticals, Inc. (PI6.F)
- Previous Close
0.1258 - Open
0.1258 - Bid 0.1360 x 500000
- Ask 0.1444 x 500000
- Day's Range
0.1258 - 0.1258 - 52 Week Range
0.1258 - 68.8800 - Volume
31,100 - Avg. Volume
11 - Market Cap (intraday)
174,122 - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-20.2700 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.50
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
www.pieris.comRecent News: PI6.F
Performance Overview: PI6.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PI6.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PI6.F
Valuation Measures
Market Cap
13.41M
Enterprise Value
-11.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.28
Price/Book (mrq)
0.50
Enterprise Value/Revenue
-0.26
Enterprise Value/EBITDA
1.08
Financial Highlights
Profitability and Income Statement
Profit Margin
-57.33%
Return on Assets (ttm)
-14.76%
Return on Equity (ttm)
-89.76%
Revenue (ttm)
42.81M
Net Income Avi to Common (ttm)
-24.54M
Diluted EPS (ttm)
-20.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
26.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-26.68M
Research Analysis: PI6.F
Company Insights: PI6.F
PI6.F does not have Company Insights